Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-12-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to estimate the relative potency for bronchoprotective effect of formoterol Novolizer 12 µg (test) compared to formoterol Aerolizer 12 µg (reference).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

NCT01043601

COPD

WITHDRAWN PHASE2

Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)

NCT00443482

Asthma

COMPLETED PHASE2

A Study Comparative of Formoterol/Fluticasone Foraseq® and Fluticasone in Asthma Patients

NCT01202084

Asthma

COMPLETED PHASE3

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

NCT01349868

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE2

A Study in Healthy Volunteers to Evaluate Serum and Urine Levels of the Investigational Product Versus Comparator.

NCT00280358

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

24 µg Formoterol Novolizer

12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2

Group Type EXPERIMENTAL

Formatris 24µg

Intervention Type DRUG

12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2

12µg Formoterol Novolizer

12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2

Group Type EXPERIMENTAL

Formatris 12µg

Intervention Type DRUG

12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2

24 µg Formoterol Aerolizer

Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2

Group Type ACTIVE_COMPARATOR

Foradil P 24µg

Intervention Type DRUG

Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2

12µg Formoterol Aerolizer

Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2

Group Type ACTIVE_COMPARATOR

Foradil P 12µg

Intervention Type DRUG

Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Formatris 24µg

12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2

Intervention Type DRUG

Formatris 12µg

12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2

Intervention Type DRUG

Foradil P 24µg

Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2

Intervention Type DRUG

Foradil P 12µg

Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patients aged from 18 to 60 years (inclusive).
2. Patients with asthma indicated by

* history of asthma symptoms and
* airway hyperresponsiveness to methacholine with a provocation concentration of methacholine that cause a 20% decrease in FEV1 (PC20) ≤8 mg/ml at Visit 1.
3. Patients with stable asthma condition with baseline forced expiratory volume in the first second (FEV1) ≥70% predicted at first visit.
4. The PC20 methacholine should increase at least 4-fold after inhaling 24 μg of formoterol Aerolizer (2 applications of 12 μg) at Visit 2.
5. Able to be taught correct inhalation technique for both devices at screening.

Exclusion Criteria

1. Known hypersensitivity to formoterol, lactose, or methacholine.
2. History of life-threatening asthma in the last three years.
3. Major malignancies including pheochromocytoma within the last 5 years. Exception will be considered where malignancies have been resolved as judged by investigator.
4. Pregnancy, breast-feeding, planned pregnancy during the study, or women of child-bearing potential not using adequate contraception. These methods include total abstinence (no sexual intercourse), oral contraceptives, an intrauterine device (IUD), an etonogestrel implant (Implanon), or medroxyprogesterone acetate injections (Depo-Provera shots). If one of these cannot be used, using contraceptive foam and a condom are recommended.

Lack of suitability for the study:
5. Screening visit 2 has to be postponed repeatedly.
6. Evidence of respiratory tract infection within 4 weeks before the study (screening visit 1).
7. Seasonal or episodic exposure to an allergen or occupational chemical sensitizer which are likely to vary in symptom presentation and severity during the course of the study (e.g. ragweed sensitive patients in Iowa during Aug-Oct). This does not apply to patients who can be well controlled on therapy.
8. History of non-reversible pulmonary disease; chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, or pulmonary fibrosis.
9. History of severe cardiovascular, renal, neurologic, liver or endocrine dysfunction (patients with well-controlled hypertension, hypercholesterolemia, thyroid disease or diabetes may be included if medication for these diseases does not affect methacholine challenge or formoterol metabolism).
10. History of hemophilia or coagulation disease.
11. Electrocardiogram (ECG) abnormalities of clinical relevance, in particular abnormal prolongation of QT-interval (QTc according to Bazett in women ≥450 msec, in men ≥430 msec).
12. Potassium level below lower limit of laboratory normal range plus 0.3 mmol/l as safety margin.
13. Exacerbation of bronchial asthma requiring emergency department visit or hospitalization during the last 3 months prior to this study.
14. Prior or concomitant treatment with systemic glucocorticosteroids during the last 3 months (a short course of oral corticosteroids for asthma is permissible if for \<10 days and at least 30 days have passed).
15. Use of long-acting ß2-agonists in last 3 weeks before the first methacholine challenge or during the study
16. Change in dosage of other controller therapy (inhaled glucocorticosteroids, leukotriene modifier, slow-release theophylline) during the last 3 weeks before the first methacholine challenge or during the study.
17. Use of short-acting ß2-agonists more than thrice a week in the previous month.
18. Inability to temporary withhold the following medications/substances before lung function test:

* short-acting ß2-agonists and short-acting anticholinergics at least 6 hours,
* regular long-acting ß2-agonists at least 3 weeks,
* long-acting anticholinergics at least 36 hours,
* inhaled glucocorticosteroids at least 2 hours
* Disodium cromoglycate (DSCG) at least 24 hours,
* slow release theophylline at least 48 hours,
* rapid release theophylline at least 24 hours,
* caffeine at least 4 hours
19. Patients with aspirin induced bronchospasm.
20. Any treatment with ß2-antagonists (including eye drops).
21. Non-cooperative patients, inability to perform outcome measurement correctly.
22. Inability to measure PC20 methacholine after 24 μg of formoterol Aerolizer (PC20 \>128 mg/ml).
23. Current smokers or regular smokers during last 12 months or more than 10 pack-year history.
24. Drug or alcohol abuse which would interfere with the patient's proper completion of the protocol assignment.

Administrative reasons:
25. Participation in another clinical study within 1 month prior to or during this study
26. Lack of ability or willingness to give informed consent.
27. Lack of willingness to have personal study related data collected, archived or transmitted according to protocol.
28. Personnel involved in the planning or conduct of the study.
29. Anticipated non-availability for study visits/procedures.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No